References
- 1. Fernández-Villar, A., Sopeña, B., Vázquez, R., Ulloa, F., Fluiters, E., Mosteiro, M., César, M.- V. & Piñeiro, L. (2003). Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C. Clinical Infectious Diseases. 36(3), 293-298. doi: 10.1086/345906.
- 2. Gronhagen-Riska, C., Hellstrom, P.E. & Froseth, B. (1978). Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis. 118(3), 461-466. doi: 10.1164/arrd.1978.118.3.461
- 3. Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Lai, S.L., Yang, S.Y., Chang, F.Y. & Lee, S.D. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 35(4), 883-889. doi: 10.1053/jhep.2002.32102
- 4. Huang, Y.S., Chern, H.D., Su, W.J., Wu, J.C., Chang, S.C., Chiang, C.H., Chang, F.Y. & Lee, S.D. (2003). Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis druginduced hepatitis. Hepatology. 37(4), 924-930. doi: 10.1053/jhep.2003.50144
- 5. Steele, M.A., Burk, R.F. & DesPrez, R.M. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 99(2), 465-471.10.1378/chest.99.2.4651824929
- 6. Yew, W.W. & Leung, C.C. (2007). Antituberculosis Drugs anbd Hepatotoxicity. Hong Kong Medical Diary, 12(1), 7-9
- 7. de Abajo, F.J., Montero, D., Madurga, M. & Garcia Rodriguez, L.A. (2004). Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58(1), 71-80. doi: 10.1111/j.1365-2125.2004.02133.x
- 8. Jobanputra, P., Amarasena, R., Maggs, F., Homer, D., Bowman, S., Rankin, E., Filer, A., Raza, K. & Jubb, R. (2008). Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 9, 48. doi: 10.1186/1471-2474-9-48
- 9. Emery, P., Breedveld, F.C., Lemmel, E.M., Kaltwasser, J.P., Dawes, P.T., Gomor, B., Van Den Bosch, F., Nordstrom, D., Bjorneboe, O., Dahl, R., Horslev-Petersen, K., Rodriguez De La Serna, A., Molloy, M., Tikly, M., Oed, C., Rosenburg, R. & Loew-Friedrich, I. (2000). A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 39(6), 655-665.10.1093/rheumatology/39.6.65510888712
- 10. Matteson, E. & Cush, J.J. (2001). Reports of leflunomide hepatotoxicity in patients with rheumatoid arthritis. ACR Hotline
- 11. Cohen, S.B. & Iqbal, I. (2003). Leflunomide. Int J Clin Pract. 57(2), 115-120.10.1111/j.1742-1241.2003.tb10439.x
- 12. Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., Fox, R., Moreland, L., Olsen, N., Furst, D., Caldwell, J., Kaine, J., Sharp, J., Hurley, F. & Loew-Friedrich, I. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 159(21), 2542-2550.10.1001/archinte.159.21.254210573044